TABLE 1.
Comparison of cell-associated and cell-free virus neutralizationa
| Env variant and antibody or inhibitor | TZM-bl assay |
A3R5 assay |
||
|---|---|---|---|---|
| Increased neutralization resistance of virus | P value | Increased neutralization resistance of virus | P value | |
| Antibodies | ||||
| BAL | ||||
| huOKT4A | CF | 6 × 10−2 | ||
| hu5A8 | CA | 4 × 10−2 | CA | 1 × 10−1 |
| 4E10 | CA | 9 × 10−3 | CA | 3 × 10−1 |
| 10E8 | CA | 2 × 10−1 | CA | 7 × 10−2 |
| VRC01 | CA | 2 × 10−7 | CA | 7 × 10−2 |
| CH01 | CF | 3 × 10−1 | CA | 3 × 10−1 |
| PGT126 | CA | 2 × 10−1 | CA | 3 × 10−3 |
| PG9 | CF | 2 × 10−1 | CA | 5 × 10−1 |
| WITO | ||||
| huOKT4A | CA | 1 × 10−4 | ||
| hu5A8 | CA | 2 × 10−3 | CA | 4 × 10−6 |
| 4E10 | CA | 3 × 10−1 | CA | 2 × 10−1 |
| 10E8 | CF | 6 × 10−1 | CA | 8 × 10−1 |
| VRC01 | CA | 5 × 10−7 | CA | 6 × 10−9 |
| CH01 | CA | 2 × 10−6 | CA | 5 × 10−6 |
| PGT126 | CF | 1 × 10−3 | CA | 2 × 10−3 |
| PG9 | CA | 2 × 10−16 | CA | 3 × 10−7 |
| CH040 | ||||
| huOKT4A | CA | 9 × 10−1 | ||
| hu5A8 | CA | 7 × 10−1 | CA | 7 × 10−4 |
| 4E10 | CF | 4 × 10−2 | CF | 7 × 10−1 |
| 10E8 | CF | 7 × 10−1 | CF | 5 × 10−3 |
| VRC01 | CA | 1 × 10−3 | CA | 4 × 10−5 |
| CH01 | CF | 2 × 10−1 | CF | 5 × 10−1 |
| PGT126 | CF | 3 × 10−2 | CA | 9 × 10−4 |
| PG9 | CA | 5 × 10−1 | CF | 9 × 10−1 |
| CH077 | ||||
| huOKT4A | CF | 3 × 10−3 | ||
| hu5A8 | CF | 8 × 10−5 | CA | 9 × 10−6 |
| 4E10 | CF | 1 × 10−2 | CF | 4 × 10−1 |
| 10E8 | CF | 6 × 10−1 | CA | 5 × 10−1 |
| VRC01 | CA | 1 × 10−3 | CA | 3 × 10−4 |
| CH01 | CF | 3 × 10−3 | CA | 3 × 10−1 |
| PGT126 | CF | 4 × 10−2 | CA | 6 × 10−11 |
| PG9 | CA | 2 × 10−6 | CA | 6 × 10−5 |
| Inhibitors | ||||
| BAL | ||||
| PMPA | CF | 7 × 10−2 | CF | 1 |
| Nevirapine | CF | 1 | CA | 8 × 10−1 |
| T-20 | CA | 6 × 10−2 | CF | 8 × 10−1 |
| TAK-779 | CA | 9 × 10−1 | CA | 4 × 10−1 |
| Maraviroc | CA | 1 × 10−1 | CF | 9 × 10−1 |
| WITO | ||||
| PMPA | CA | 3 × 10−1 | CA | 4 × 10−1 |
| Nevirapine | CA | 9 × 10−2 | CA | 9 × 10−4 |
| T-20 | CF | 2 × 10−1 | CA | 7 × 10−3 |
| TAK-779 | CF | 4 × 10−1 | CA | 9 × 10−3 |
| Maraviroc | CA | 5 × 10−1 | CA | 1 × 10−4 |
| CH040 | ||||
| PMPA | CF | 6 × 10−3 | CA | 2 × 10−1 |
| Nevirapine | CF | 1 | CA | 2 × 10−2 |
| T-20 | CA | 1 × 10−4 | CA | 3 × 10−2 |
| TAK-779 | CA | 2 × 10−2 | CA | 2 × 10−3 |
| Maraviroc | CF | 3 × 10−2 | CA | 5 × 10−4 |
| CH077 | ||||
| PMPA | CF | 3 × 10−1 | CF | 5 × 10−1 |
| Nevirapine | CA | 9 × 10−2 | CA | 5 × 10−1 |
| T-20 | CF | 6 × 10−1 | CA | 4 × 10−1 |
| TAK-779 | CF | 4 × 10−3 | CA | 6 × 10−1 |
| Maraviroc | CF | 4 × 10−8 | CA | 5 × 10−1 |
a
Shown are the P values from the stratified exact Wilcoxon signed-rank test for each combination of 1 of the 13 neutralizing antibodies or inhibitors used against each Env variant in the TZM-bl or A3R5 assay. Boldface entries with P values are significant after Holm's adjustment. Of the 100 comparisons performed, the difference in resistance to neutralization of cell-associated (CA) versus cell-free (CF) virus was significant in 40% of total comparisons. Blank entries represent cases in which an antibody was not used in the A3R5 assay.